Clinical trials: Liraglutide
Obesity
Individualized Obesity Pharmacotherapy
The researchers are trying to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss.
- Trial name
- NCT03374956
- Testing
- Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion
- Where
- United States
- Volunteers
- 193 people
- Sponsor
- Mayo Clinic
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome
This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome.
- Trial name
- NCT02527200
- Testing
- liraglutide
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 56 people
- Sponsor
- Novo Nordisk A/S
Obese, Overweight
The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients
This is a multicenter, randomized, double-blind, placebo controlled trial to evaluate the effect and safety of Liraglutide Injection on body weight loss compared with placebo in obese or overweight adult patients with comorbidity…
- Trial name
- NCT04605861
- Testing
- Liraglutide
- Where
- China
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Overweight, Obesity
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years.
- Trial name
- STEP 8 (NCT04074161)
- Testing
- Semaglutide, Liraglutide
- Where
- 19 sites in United States
- Volunteers
- 338 people
- Sponsor
- Novo Nordisk A/S
Metformin, Obesity, Abdominal
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus
The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.
- Conditions
- Metformin, Obesity, Abdominal, Diabetes Mellitus, Type 2, Abdominal Fat
- Trial name
- NCT05779644
- Testing
- Liraglutide, Semaglutide, Metformin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- RenJi Hospital
Prediabetes, Type 2 Diabetes
RISE Adult Medication Study
The RISE Adult Medication Study is a 4-arm, 3-center, clinical trial of adults with prediabetes and early type 2 diabetes to address the hypothesis that aggressive glucose lowering will lead to recovery of beta-cell function that…
- Trial name
- RISE Adult (NCT01779362)
- Testing
- Metformin, Liraglutide, Glargine
- Where
- 4 sites in United States
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- RISE Study Group
Diabetes Mellitus, Type 2, Hemodialysis
Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients
Diabetes is the second leading cause of end stage renal disease in France (22% in the 2016 REIN register). In hemodialysis, its prevalence is higher, between 30-40% depending on the study.
- Conditions
- Diabetes Mellitus, Type 2, Hemodialysis, Obese
- Trial name
- LIRADIAL (NCT04529278)
- Testing
- Liraglutide
- Where
- 4 sites in France
- Volunteers
- 18 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Type1 Diabetes Mellitus, Autoimmune Diabetes
Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes
The purpose of this study is to investigate the safety and therapeutic effect of ex-vivo expanded umbilical cord blood regulatory T cells adjunct with Liraglutide on autoimmune diabetes.
- Trial name
- NCT03011021
- Testing
- Liraglutide, UCB-Treg, Insulin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Xiangya Hospital of Central South University
Diabetes Mellitus, Type 2 Treated With Insulin
Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue
The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent but at the same time safe drug that reduces the risk of hypoglycemia when compared to a basal or basal-bolus insulin schedule.
- Trial name
- NCT05767255
- Testing
- insulin degludec + liraglutide, Insulin Glargine - Insulin Aspart
- Where
- Colombia
- Volunteers
- 66 people
- Sponsor
- Hospital Universitario San Ignacio
Diabetes Mellitus, Type 1
Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus
The aim of the trail is investigate the effect of liraglutide 1.8mg as add-on to insulin for 6 months on carotid intima media thickness and cardiovascular risk factors in subjects with type 1 diabetes mellitus.
- Trial name
- NCT05467514
- Testing
- Liraglutide
- Where
- Mexico
- Volunteers
- 35 people
- Sponsor
- David Sanchez Garcia
Healthy
A Study of LY3537021 in Healthy Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3537021 when administered in combination with glucagon-like peptide (GLP-1) receptor agonist called liraglutide in treatment-naïve healthy…
- Trial name
- NCT05444569
- Testing
- LY3537021, Liraglutide
- Where
- Singapore
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes
The majority of people with type 2 diabetes (T2D) are overweight, and while weight gain is a major contributor to diabetes, a minority of patients with T2D are not overweight or obese.
- Trial name
- Lean-DM (NCT04657939)
- Testing
- Liraglutide, Pioglitazone
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- University of Leeds
Type 2 Diabetes, Incretinomimetics
Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.
Incretinomimetics and inhibitors of dipeptidyl peptidase-4 (DPP-4) are new treatments for diabetes. Previous retrospective studies have shown that these treatments induced an increase in pancreatic mass with potentially a risk…
- Conditions
- Type 2 Diabetes, Incretinomimetics, Pancreas
- Trial name
- NCT02244164
- Testing
- Incretinomimetics, DPP-4 inhibitors
- Where
- Belgium
- Volunteers
- 5 people
- Sponsor
- Erasme University Hospital
Ischemic Stroke, Transient Ischemic Attack
Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus
The purpose of this study is to assess the safety and efficacy of glucagon-like peptide-1 (GLP-1) analogue liraglutide in the treatment of acute minor stroke (National Institute of Health stroke scale, NIHSS ≤ 3) or high-risk…
- Conditions
- Ischemic Stroke, Transient Ischemic Attack, Type 2 Diabetes Mellitus
- Trial name
- LAMP (NCT03948347)
- Testing
- Liraglutide
- Where
- China
- Volunteers
- 1,708 people
- Sponsor
- First Affiliated Hospital of Jinan University
Obesity
POSE2.0 With GLP-1 Agonist for Obesity Management
Determine the effect on weight loss and obesity-related comorbidities in patients receiving the POSE 2.0 procedure with sequential use of Liraglutide at 6 months compared to those receiving Liraglutide and then undergoing the…
- Trial name
- NCT05705388
- Testing
- POSE2.0 Endoscopic Gastric Remodeling, Liraglutide injection
- Where
- United Arab Emirates
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Emirates Health Services (EHS)
Obesity
INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records
The study is investigating the use of Saxenda (liragltuide 3.0 milligrams (mg) once daily) for weight management. The primary objective is to investigate the change in body weight after initiation and use of Saxenda ® according…
- Trial name
- INSPIRE Turkey (NCT05438186)
- Testing
- Liraglutide
- Where
- Turkey (Türkiye)
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Obesity
In-market Utilisation of Liraglutide Used for Weight Management in Europe
This study is conducted in Europe. The aim of this study is to investigate usage of liraglutide for weight management in clinical practice.
- Trial name
- NCT02967757
- Testing
- liraglutide
- Where
- 19 sites in Germany, Italy
- Volunteers
- 316 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
This trial is conducted in Asia. The aim of this trial is to confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral…
- Trial name
- DUAL™ I China (NCT03172494)
- Testing
- Insulin degludec/liraglutide, Insulin degludec, Liraglutide
- Where
- 36 sites in China
- Volunteers
- 720 people
- Sponsor
- Novo Nordisk A/S
Obesity
Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery
This is a randomized, double-blinded, placebo-controlled trial of liraglutide versus placebo over a follow-up period of 12 months in patients at least 18 months following Roux-en-Y gastric bypass (RYGB) who are experiencing…
- Trial name
- NCT03048578
- Testing
- Saxenda
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- NYU Langone Health
Obesity, Overweight
In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database
This study is conducted in Europe. The aim of this study is to investigate the usage of liraglutide for weight management in clinical practice using the CPRD (Clinical Practice Research Datalink) primary care database.
- Trial name
- NCT03479762
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 105 people
- Sponsor
- Novo Nordisk A/S